Transdermal Drug Delivery Systems Market - By Type By Application By End-use & Forecast, 2023

Description

List of Tables

Global Transdermal Drug Delivery System Market is expected to exhibit a decent CAGR from 2023 to 2032, owing to the rising demand for non-invasive drug delivery systems. Oral, topical, transdermal, and other non-invasive drug delivery methods are painless and demonstrate fewer side effects than invasive procedures. These attributes have added to the popularity of these systems over the years and boosted their adoption among patients with higher dependency on self-administration and improved patient compliance due to reduced dosing frequencies.

The overall transdermal drug delivery system market is categorized on the basis of type, application, end-use, and region.

Regarding the type, the transdermal drug delivery system market size from the semisolids segment is anticipated to garner commendable gains through 2032. Semisolid transdermal drug delivery products such as sprays enable direct drug delivery and have lesser side effects. Additionally, they help administer pre-measured doses in patients for better treatment. Moreover, the high availability of a wide range of semi-solid transdermal drug delivery products such as ointment, gels, sprays, and others will favor their adoption through 2032.

With respect to application, the cardiovascular diseases segment accumulated over 19% market share in 2022. High prevalence rate of cardiovascular disorders (CVDs) globally will increase product uptake in the forthcoming years. As per WHO, CVDs are a prominent cause of death, resulting in around 17.9 million mortalities across the globe annually. Moreover, the increased acceptance of non-invasive drug delivery devices for the treatment of these diseases will further create a strong growth outlook for the transdermal drug delivery system market.

Based on end-use, the transdermal drug delivery system industry from home care settings segment could record a decent valuation by 2032. Recent innovations in transdermal drug delivery systems have fostered their adoption in home care applications. These drug delivery systems reduce the risks and discomfort associated with the parenteral route of administration, making them suitable for home usage. This apart, the increasing demand for minimally invasive treatment will further contribute to strong product demand in the long run.

Asia Pacific transdermal drug delivery system market is poised to expand substantially through 2032. Rising geriatric population and its higher susceptibility to chronic disorders have increased the demand for transdermal drug delivery systems in the region. According to WHO, 28% of the total population in China will be above 60 years by 2040. Asia Pacific is also home to key industry players such as Hisamitsu Pharmaceutical Co., Inc. and others constantly indulged in product innovations. This will also have a positive impact on the overall market dynamics in the coming years.

Product Code: 5548

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope and definitions
1.3 Base estimates and working
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Transdermal drug delivery systems industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Type trends
- 2.1.3 Application trends
- 2.1.4 End-use trends
- 2.1.5 Regional trends

Chapter 3 Transdermal Drug Delivery Systems Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Increasing prevalence of chronic diseases
  - 3.3.1.2 Increasing adoption of transdermal patches
  - 3.3.1.3 Growing demand for non-invasive drug delivery system
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Limited number of approved medications
  - 3.3.2.2 High cost involved in development of drug delivery systems
3.4 Growth potential analysis
- 3.4.1 By type
- 3.4.2 By application
- 3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.7 Advancement in transdermal drug delivery systems
3.8 Transdermal forms containing the specified active substance, %
3.9 Pricing analysis, by type, 2022
3.10 Porter's analysis
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2021

4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Company positioning matrix
4.4 Competitive analysis of major market players
4.5 Strategic outlook matrix
4.6 Strategy dashboard, 2021

Chapter 5 Transdermal Drug Delivery Systems Market, By Type

5.1 Key type trends
5.2 Transdermal patches
- 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.2 Drug-in-adhesive patches
  - 5.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.3 Matrix patches
  - 5.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.4 Reservoir membrane patches
  - 5.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.2.5 Microneedle patches
  - 5.2.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Transdermal semisolids
- 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.2 Gels
  - 5.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.3 Ointments
  - 5.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3.4 Sprays
  - 5.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6 Transdermal Drug Delivery Systems Market, By Application

6.1 Key application trends
6.2 Pain management
- 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Hormonal application
- 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Central nervous system disorders
- 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Cardiovascular diseases
- 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Others
- 6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7 Transdermal Drug Delivery Systems Market, By End-use

7.1 Key end-use trends
7.2 Hospitals
- 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Clinics
- 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Homecare settings
- 7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.5 Others
- 7.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8 Transdermal Drug Delivery Systems Market, By Region

8.1 Key regional trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Poland
- 8.3.7 Switzerland
- 8.3.8 The Netherlands
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Indonesia
- 8.4.7 Thailand
- 8.4.8 Vietnam
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Peru
- 8.5.5 Colombia
8.6 Middle East & Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Israel

Chapter 9 Company Profiles

9.1 Novartis
9.2 Mylan
9.3 Amneal Pharmaceuticals, Inc
9.4 Zydus Pharmaceuticals, Inc
9.5 UCB
9.6 Hisamitsu Pharmaceutical Co.,Inc
9.7 Corium, Inc.
9.8 Micropoint Technologies.
9.9 Sparsha Pharma International Pvt. Ltd.
9.10 Luye pharma